BR112022020798A2 - Compostos tricíclicos como inibidores de nlrp3 - Google Patents
Compostos tricíclicos como inibidores de nlrp3Info
- Publication number
- BR112022020798A2 BR112022020798A2 BR112022020798A BR112022020798A BR112022020798A2 BR 112022020798 A2 BR112022020798 A2 BR 112022020798A2 BR 112022020798 A BR112022020798 A BR 112022020798A BR 112022020798 A BR112022020798 A BR 112022020798A BR 112022020798 A2 BR112022020798 A2 BR 112022020798A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- inhibitors
- nlrp3
- tricyclic compounds
- nlrp3 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTOS TRICÍCLICOS COMO INIBIDORES DE NLRP3. A presente invenção refere-se a compostos inovadores para uso como inibidores da produção de inflamassoma de NLRP3, em que tais compostos são conforme definidos pelos compostos da fórmula (I) e em que os números inteiros R1, R2 e R3 são definidos na descrição, e em que os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento de uma doença ou transtorno que é associado à atividade de inflamassoma de NLRP3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382332 | 2020-04-23 | ||
| PCT/EP2021/060649 WO2021214284A1 (en) | 2020-04-23 | 2021-04-23 | Tricyclic compounds as inhibitors of nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020798A2 true BR112022020798A2 (pt) | 2022-11-29 |
Family
ID=70480193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020798A BR112022020798A2 (pt) | 2020-04-23 | 2021-04-23 | Compostos tricíclicos como inibidores de nlrp3 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230203064A1 (pt) |
| EP (1) | EP4139312A1 (pt) |
| JP (1) | JP2023523418A (pt) |
| KR (1) | KR20230005252A (pt) |
| CN (1) | CN115461345A (pt) |
| AU (1) | AU2021260115A1 (pt) |
| BR (1) | BR112022020798A2 (pt) |
| CA (1) | CA3176029A1 (pt) |
| MX (1) | MX2022013323A (pt) |
| WO (1) | WO2021214284A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023044043A1 (en) * | 2021-09-17 | 2023-03-23 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023156643A1 (en) * | 2022-02-21 | 2023-08-24 | Sanofi | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| BR112021001044A2 (pt) | 2018-07-20 | 2021-04-13 | F. Hoffmann-La Roche Ag | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 |
| EP3827008A1 (en) | 2018-07-25 | 2021-06-02 | Novartis AG | Nlrp3 inflammasome inhibitors |
| US20220098188A1 (en) | 2018-08-17 | 2022-03-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors |
-
2021
- 2021-04-23 WO PCT/EP2021/060649 patent/WO2021214284A1/en unknown
- 2021-04-23 EP EP21720494.0A patent/EP4139312A1/en active Pending
- 2021-04-23 CA CA3176029A patent/CA3176029A1/en active Pending
- 2021-04-23 CN CN202180030419.XA patent/CN115461345A/zh active Pending
- 2021-04-23 KR KR1020227040740A patent/KR20230005252A/ko active Search and Examination
- 2021-04-23 JP JP2022564129A patent/JP2023523418A/ja active Pending
- 2021-04-23 BR BR112022020798A patent/BR112022020798A2/pt unknown
- 2021-04-23 US US17/996,633 patent/US20230203064A1/en active Pending
- 2021-04-23 MX MX2022013323A patent/MX2022013323A/es unknown
- 2021-04-23 AU AU2021260115A patent/AU2021260115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115461345A (zh) | 2022-12-09 |
| US20230203064A1 (en) | 2023-06-29 |
| WO2021214284A1 (en) | 2021-10-28 |
| CA3176029A1 (en) | 2021-10-28 |
| KR20230005252A (ko) | 2023-01-09 |
| MX2022013323A (es) | 2022-11-30 |
| JP2023523418A (ja) | 2023-06-05 |
| AU2021260115A1 (en) | 2023-01-05 |
| EP4139312A1 (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023271A2 (pt) | Compostos | |
| BR112022020776A2 (pt) | Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3 | |
| BR112022020798A2 (pt) | Compostos tricíclicos como inibidores de nlrp3 | |
| BR112022021881A2 (pt) | Novos compostos de triazinoindol | |
| BR112022020807A2 (pt) | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| BRPI0513086A (pt) | 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112013003097A2 (pt) | 6-cicloalquil-pirazolopirimidemonas para o tratamento de distúrbio de cns | |
| BR112012030024A2 (pt) | compostos, processo para a preparação de um composto, medicamento | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112022019057A2 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune | |
| BR112022024045A2 (pt) | Moduladores il-17a | |
| BR112022023983A2 (pt) | Compostos terapêuticos | |
| BR112022003799A2 (pt) | Compostos antibacterianos | |
| BR112023019030A2 (pt) | Derivados de fósforo como inibidores de sos1 | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| BR112023018654A2 (pt) | Compostos antibacterianos | |
| BR112016008158A2 (pt) | Moduladores de ror-gama-t de quinolinila ligados a metileno |